Vireo Growth (VREOF) Non Operating Income (2020 - 2026)
Vireo Growth (VREOF) posted Non Operating Income of -$13.2 million for Q1 2026, down 203.72% sequentially from $12.7 million in Q4 2025, and down 230.0% YoY from $10.2 million in Q1 2025.
Vireo Growth (VREOF) Non Operating Income (2020 - 2026) Analysis & Trends
Vireo Growth has reported Non Operating Income for 7 years, with the latest figure at -$13.2 million in Q1 2026.
- Quarterly Non Operating Income fell 230.0% year-over-year to -$13.2 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$22.3 million (up 17.21% YoY) and the FY2025 annual result came in at -$15.9 million, up 47.78% from the prior year.
- Non Operating Income retreated to -$13.2 million in Q1 2026 per VREOF's latest filing, from $12.7 million in the prior quarter.
- Over five years, Non Operating Income peaked at $12.7 million in Q4 2025 and troughed at -$13.8 million in Q3 2025.
- A 5-year average of -$6.8 million and a median of -$7.6 million in 2022 frame the typical range for Non Operating Income.
- The sharpest annual moves came in 2022 and 2025: Non Operating Income plunged 1505.39% in 2022, then jumped 221.01% in 2025.
- Over 5 years, Non Operating Income stood at -$8.0 million in 2022, then dropped by 11.68% to -$9.0 million in 2023, then dropped by 17.16% to -$10.5 million in 2024, then surged by 221.01% to $12.7 million in 2025, then plunged by 203.72% to -$13.2 million in 2026.
- According to Business Quant data, Non Operating Income over the past three periods registered -$13.2 million, $12.7 million, and -$13.8 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non Op. Inc. (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 43.81 Bn | 42.84 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 43.29 Bn | 39.63 Bn | 2.15 Bn | -224.00 Mn |
| 3 | Zoetis | 31.59 Bn | 29.91 Bn | 1.05 Bn | 5.00 Mn |
| 4 | Takeda Pharmaceutical | 28.67 Bn | 22.88 Bn | 5.10 Bn | - |
| 5 | United Therapeutics | 22.24 Bn | 19.58 Bn | 683.80 Mn | 41.90 Mn |
| 6 | Viatris | 18.79 Bn | 17.91 Bn | 1.46 Bn | - |
| 7 | Neurocrine Biosciences | 15.71 Bn | 15.32 Bn | 935.80 Mn | 10.70 Mn |
| 8 | Elanco Animal Health | 12.09 Bn | 11.56 Bn | 798.00 Mn | - |
| 9 | Dr Reddys Laboratories | 10.11 Bn | 9.95 Bn | - | - |
| 10 | Vireo Growth | 492.80 Mn | 350.50 Mn | 95.30 Mn | 20.50 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -13.20 Mn |
| Dec 31, 2025 | 12.73 Mn |
| Sep 30, 2025 | -13.76 Mn |
| Jun 30, 2025 | -8.06 Mn |
| Mar 31, 2025 | -4.00 Mn |
| Dec 31, 2024 | -10.52 Mn |
| Sep 30, 2024 | -6.39 Mn |
| Jun 30, 2024 | -6.02 Mn |
| Mar 31, 2024 | -7.53 Mn |
| Dec 31, 2023 | -8.98 Mn |
| Sep 30, 2023 | -7.62 Mn |
| Jun 30, 2023 | -4.69 Mn |
| Mar 31, 2023 | -7.11 Mn |
| Dec 31, 2022 | -8.04 Mn |
| Sep 30, 2022 | -7.59 Mn |
| Jun 30, 2022 | -5.45 Mn |
| Mar 31, 2022 | -8.55 Mn |
| Dec 31, 2021 | -3.52 Mn |
| Sep 30, 2021 | -2.18 Mn |
| Jun 30, 2021 | -2.85 Mn |